Back to top
more

AngioDynamics (ANGO)

(Real Time Quote from BATS)

$7.13 USD

7.13
119,645

-0.28 (-3.78%)

Updated Nov 7, 2024 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics Divests NAMIC Portfolio to Medline Industries

by Zacks Equity Research

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

AngioDynamics IDE Application for NanoKnife Gets FDA Nod

by Zacks Equity Research

AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

    Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?

    by Zacks Equity Research

    AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates

    by Zacks Equity Research

    Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.

    AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study

    by Zacks Equity Research

    AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.

    AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

    AngioDynamics' Latest FDA Approval to Boost Oncology Unit

    by Zacks Equity Research

    AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.

    Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down

    by Zacks Equity Research

    Avanos (AVNS) registers solid growth in the Chronic Care and Pain Management segments in Q4.

    AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates

    by Zacks Equity Research

    AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.

    Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y

    by Zacks Equity Research

    Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.

    GNC Holdings' (GNC) Q4 Earnings Miss Estimates, Margins Fall

    by Zacks Equity Research

    GNC Holdings' (GNC) international segment registers revenue growth in the fourth quarter.

    Here's Why You Should Invest in AngioDynamics Stock Now

    by Zacks Equity Research

    Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.

    HMS Holdings' (HMSY) Q4 Earnings Beat, Revenues Rise Y/Y

    by Zacks Equity Research

    Strong performance in Analytical Services drove HMS Holdings' (HMSY) performance in Q4.

    PRA Health's (PRAH) Q4 Earnings Top, Revenues Lag Estimates

    by Zacks Equity Research

    PRA Health (PRAH) gains from solid segmental contributions in Q4.

    Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up

    by Zacks Equity Research

    Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.

    OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues

    by Zacks Equity Research

    OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.

    Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4

    by Zacks Equity Research

    Penumbra (PEN) sees strength across all segments in Q4.

    Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4

    by Zacks Equity Research

    Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.

    Patterson Companies (PDCO) Earnings Match Estimates in Q3

    by Zacks Equity Research

    Patterson Companies (PDCO) gains from solid segmental contributions in Q3.

    Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4

    by Zacks Equity Research

    At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.

      Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

      by Zacks Equity Research

      Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.